Overcoming cell death resistance in skin cancer therapy: Novel translational perspectives.
In the last decade, significant progress has been made in understanding skin cancer cell death resistance mechanisms, and a number of new treatment strategies have been developed. Systematic approach genomic studies of various cancer types have opened new possibilities for the development of anticancer therapies. However, there are still fundamental gaps in the challenging biomedical puzzle, which will form a complete picture for curing cancer. Thus, herein, we describe some of the current cancer treatment strategies and discuss additional cell signalling pathways that could be potential targets for skin cancer treatment.
Department of Dermatology & Allergology, University Hospital of RWTH Aachen University, Aachen, Germany.
Maria
0000-0001-7889-9907
M
Feoktistova
Department of Dermatology & Allergology, University Hospital of RWTH Aachen University, Aachen, Germany.
Diana
D
Panayotova-Dimitrova
D053446:CASP8 and FADD-Like Apoptosis Regulating Protein / Q000037:antagonists & inhibitors / Q000378:metabolism; D016923:Cell Death; D049109:Cell Proliferation; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000627:therapeutic use; D020935:MAP Kinase Signaling System; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors; D015398:Signal Transduction; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000503:physiopathology
D053446:CASP8 and FADD-Like Apoptosis Regulating Protein; D051034:Inhibitor of Apoptosis Proteins; D016328:NF-kappa B; D047428:Protein Kinase Inhibitors; D019253:Proto-Oncogene Proteins c-bcl-2

squamous cell carcinoma
; apoptosis; cancer therapy; melanoma; necroptosis